The Medicines and Healthcare products Regulatory Agency (MHRA) said last week there have been ‘no reported adverse incidents' but was due to issue a medical device alert.
In the post-launch study the mobile-phone sized monitors ‘did not produce equivalent performance to the claims in the product labelling,' Unipath said.
Patients' International Normalised Ratio (INR) of blood clotting could be wrongly estimated, putting them at risk of undermedication and the possibility of recurrent thrombosis or embolism.
SmartCheck meters were used by up to 100 surgeries providing near-patient testing for patients on anticoagulation therapy. The surgeries will be invited to switch to the Hemosense INRatio system.
Prisca.middlemiss@haymarket.com
Comment below and tell us what you think
Quick search - use * for an abbreviated search, eg nico*
With spiralling energy costs, it is important to adopt policies that can save money as well as the e... Read More
A radical programme promises to transform care for people with diabetes, writes Fiona Barr. Read More
Health and education are working together to improve young people's health and wellbeing, writes Sar... Read More
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more
Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more
Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more
Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more
Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more
This site is intended for healthcare professionals only
Comments
Only registered users may comment. Log in now or register for a free account.